Noopept Reference

Plain English

What it is

Noopept is a lab-made compound developed in Russia and used as a nootropic, which is a so-called brain or smart drug built from the structure of an older compound called piracetam. It is not approved by the FDA in the United States. In Russia it is registered as a medicine for memory and thinking problems caused by brain disorders, while in the US it is not approved as a drug and the FDA does not treat racetam-type substances like it as legal dietary supplements.

What people use it for

People in the nootropic community use it hoping to sharpen memory, attention, and focus, and many describe it as feeling stronger by weight than older racetam compounds like piracetam. Some pair it with a choline source to ease the headaches that are one of the more common complaints.

What the science shows

A single open-label Russian study in people with mild memory and thinking problems reported modest improvements in mood and cognition, and animal studies suggest it raises brain growth factors (BDNF and NGF) and may protect brain cells. But the clinical evidence is thin and low quality, there is no solid research showing it helps healthy people, and Western scientists have not independently confirmed the benefits.

The catch

Noopept is not FDA-approved, and its long-term safety in healthy people has not been studied. In the limited clinical data, reported side effects included trouble sleeping, irritability, and raised blood pressure, and headache is a frequent complaint.

Reference summary

Russian-language clinical literature reports modest improvements in attention, memory, and emotional-volitional symptoms across cohorts with mild cognitive impairment, post-stroke cognitive symptoms, and asthenic states (Neznamov 2009, Amelin 2011, Kovalev 2008, Ostrovskaya 2007 review). Mechanistically, noopept and its primary active metabolite cycloprolylglycine are reported to enhance BDNF and NGF expression and modulate AMPA receptors in rodent models, framing the community nootropic positioning. Western peer-reviewed replication is thin, with effect sizes smaller than the Russian indication implies. No outcome-grade data outside the Russian regulatory context.

Regulatory and posture

Categories

Nootropic, Cognitive

Aliases

GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam

Evidence posture

human - Not FDA-approved in the US. Russian regulatory approval. Community nootropic framing extrapolates beyond the approved cognitive-impairment indication. Most clinical evidence is Russian-language, lower-quality methodologically, and not independently replicated in Western trials.

Regulatory status

No FDA-approved noopept drug label. Russian-approved for organic disorders of the central nervous system with cognitive impairment under the brand Noopept (originally developed at the Russian Academy of Medical Sciences by Ostrovskaya and collaborators). Sold internationally as a research-chemical or nootropic supplement; not a US dietary-supplement category match.

Content review status

research reference